Semagacestat

Research use only, not for human use.

A potent γ-secretase inhibitor that inhibits β-amyloid Aβ42, Aβ38 and Aβ40 with IC50 of 10.9, 12 and 12.1 nM, respectively.

A potent γ-secretase inhibitor that inhibits β-amyloid Aβ42, Aβ38 and Aβ40 with IC50 of 10.9, 12 and 12.1 nM, respectively; reduces the secretion of Aβ42, Aβ40, and Aβ38 in cells and increases β-CTF in cell lysates, also inhibits Notch signaling with IC50 of 14.1 nM; increases intracellular byproduct peptides, produced along with Aβ through serial γ-cleavage of βAPP, as well as intracellular long Aβ species, in cell-based and in vivo studies of AD model mice; a pseudo-inhibitor of γ-secretase.Alzheimer's Disease Phase 3 Discontinued

LY450139;LY-450139

Wnt/Notch/Hedgehog

γ-secretase

Notch;γsecretase(Aβ38);γsecretase(Aβ40);γsecretase(Aβ42)

Neurological Disease

Alzheimer Disease

425386-60-3

361.44

C19H27N3O4

>98% (HPLC)

10 mM in DMSO

CC(C)[C@H](O)C(N[C@@H](C)C(N[C@@H]1C(N(C)CCC2=CC=CC=C12)=O)=O)=O

Butanamide, 2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, (2S)-

(-20℃)

With Ice Pack

≥ 2 years